Versant Ventures and AstraZeneca led a $110m Series A round in SixPeaks Bio.

Versant Venturesm, a venture capital firm, and AstraZeneca, a biopharmaceutical business, led a $110m Series A round in SixPeaks Bio, a biotechnology company. “We are proud to debut SixPeaks, which has developed a pipeline of impactful future medicines for healthy weight loss. In addition, we are very excited to be working with AstraZeneca, whose development capabilities and commitment to this space made them our partner of choice," Philip Larsen, SixPeaks Bio CEO.